These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 23995783)

  • 1. Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase.
    Weizman N; Krelin Y; Shabtay-Orbach A; Amit M; Binenbaum Y; Wong RJ; Gil Z
    Oncogene; 2014 Jul; 33(29):3812-9. PubMed ID: 23995783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lurbinectedin induces depletion of tumor-associated macrophages, an essential component of its in vivo synergism with gemcitabine, in pancreatic adenocarcinoma mouse models.
    Céspedes MV; Guillén MJ; López-Casas PP; Sarno F; Gallardo A; Álamo P; Cuevas C; Hidalgo M; Galmarini CM; Allavena P; Avilés P; Mangues R
    Dis Model Mech; 2016 Dec; 9(12):1461-1471. PubMed ID: 27780828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis.
    Xian G; Zhao J; Qin C; Zhang Z; Lin Y; Su Z
    Cancer Lett; 2017 Jan; 385():65-74. PubMed ID: 27840243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue Transglutaminase Activates Cancer-Associated Fibroblasts and Contributes to Gemcitabine Resistance in Pancreatic Cancer.
    Lee J; Yakubov B; Ivan C; Jones DR; Caperell-Grant A; Fishel M; Cardenas H; Matei D
    Neoplasia; 2016 Nov; 18(11):689-698. PubMed ID: 27792935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Macrophage-Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer.
    Halbrook CJ; Pontious C; Kovalenko I; Lapienyte L; Dreyer S; Lee HJ; Thurston G; Zhang Y; Lazarus J; Sajjakulnukit P; Hong HS; Kremer DM; Nelson BS; Kemp S; Zhang L; Chang D; Biankin A; Shi J; Frankel TL; Crawford HC; Morton JP; Pasca di Magliano M; Lyssiotis CA
    Cell Metab; 2019 Jun; 29(6):1390-1399.e6. PubMed ID: 30827862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MiR-608 regulating the expression of ribonucleotide reductase M1 and cytidine deaminase is repressed through induced gemcitabine chemoresistance in pancreatic cancer cells.
    Rajabpour A; Afgar A; Mahmoodzadeh H; Radfar JE; Rajaei F; Teimoori-Toolabi L
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):765-775. PubMed ID: 28887583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transfer of miRNA in Macrophage-Derived Exosomes Induces Drug Resistance in Pancreatic Adenocarcinoma.
    Binenbaum Y; Fridman E; Yaari Z; Milman N; Schroeder A; Ben David G; Shlomi T; Gil Z
    Cancer Res; 2018 Sep; 78(18):5287-5299. PubMed ID: 30042153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer.
    Neesse A; Frese KK; Bapiro TE; Nakagawa T; Sternlicht MD; Seeley TW; Pilarsky C; Jodrell DI; Spong SM; Tuveson DA
    Proc Natl Acad Sci U S A; 2013 Jul; 110(30):12325-30. PubMed ID: 23836645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-associated macrophage-secreted 14-3-3ζ signals via AXL to promote pancreatic cancer chemoresistance.
    D'Errico G; Alonso-Nocelo M; Vallespinos M; Hermann PC; Alcalá S; García CP; Martin-Hijano L; Valle S; Earl J; Cassiano C; Lombardia L; Feliu J; Monti MC; Seufferlein T; García-Bermejo L; Martinelli P; Carrato A; Sainz B
    Oncogene; 2019 Jul; 38(27):5469-5485. PubMed ID: 30936462
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Tadros S; Shukla SK; King RJ; Gunda V; Vernucci E; Abrego J; Chaika NV; Yu F; Lazenby AJ; Berim L; Grem J; Sasson AR; Singh PK
    Cancer Res; 2017 Oct; 77(20):5503-5517. PubMed ID: 28811332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracellular Cytidine Deaminase Regulates Gemcitabine Metabolism in Pancreatic Cancer Cell Lines.
    Bjånes TK; Jordheim LP; Schjøtt J; Kamceva T; Cros-Perrial E; Langer A; Ruiz de Garibay G; Kotopoulis S; McCormack E; Riedel B
    Drug Metab Dispos; 2020 Mar; 48(3):153-158. PubMed ID: 31871136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Casein Kinase 1 Delta Sensitizes Pancreatic and Bladder Cancer Cells to Gemcitabine Treatment by Upregulating Deoxycytidine Kinase.
    Vena F; Bayle S; Nieto A; Quereda V; Aceti M; Frydman SM; Sansil SS; Grant W; Monastyrskyi A; McDonald P; Roush WR; Teng M; Duckett D
    Mol Cancer Ther; 2020 Aug; 19(8):1623-1635. PubMed ID: 32430484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Periostin promotes the chemotherapy resistance to gemcitabine in pancreatic cancer.
    Liu Y; Li F; Gao F; Xing L; Qin P; Liang X; Zhang J; Qiao X; Lin L; Zhao Q; Du L
    Tumour Biol; 2016 Nov; 37(11):15283-15291. PubMed ID: 27696296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors.
    Samulitis BK; Pond KW; Pond E; Cress AE; Patel H; Wisner L; Patel C; Dorr RT; Landowski TH
    Cancer Biol Ther; 2015; 16(1):43-51. PubMed ID: 25485960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective disruption of rb-raf-1 kinase interaction inhibits pancreatic adenocarcinoma growth irrespective of gemcitabine sensitivity.
    Treviño JG; Verma M; Singh S; Pillai S; Zhang D; Pernazza D; Sebti SM; Lawrence NJ; Centeno BA; Chellappan SP
    Mol Cancer Ther; 2013 Dec; 12(12):2722-34. PubMed ID: 24107447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SMYD2 Imparts Gemcitabine Resistance to Pancreatic Adenocarcinoma Cells by Upregulating EVI2A.
    Jin L; Qian D; Tang X; Huang Y; Zou J; Wu Z
    Mol Biotechnol; 2024 Oct; 66(10):2920-2933. PubMed ID: 37812330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.
    Liu M; Zhang Y; Yang J; Cui X; Zhou Z; Zhan H; Ding K; Tian X; Yang Z; Fung KA; Edil BH; Postier RG; Bronze MS; Fernandez-Zapico ME; Stemmler MP; Brabletz T; Li YP; Houchen CW; Li M
    Gastroenterology; 2020 Feb; 158(3):679-692.e1. PubMed ID: 31711924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytidine deaminases APOBEC3C and APOBEC3D promote DNA replication stress resistance in pancreatic cancer cells.
    Ubhi T; Zaslaver O; Quaile AT; Plenker D; Cao P; Pham NA; Békési A; Jang GH; O'Kane GM; Notta F; Moffat J; Wilson JM; Gallinger S; Vértessy BG; Tuveson DA; Röst HL; Brown GW
    Nat Cancer; 2024 Jun; 5(6):895-915. PubMed ID: 38448522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells.
    Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE
    Clin Cancer Res; 2004 Apr; 10(7):2307-18. PubMed ID: 15073106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined blockade of TGf-β1 and GM-CSF improves chemotherapeutic effects for pancreatic cancer by modulating tumor microenvironment.
    Liu Q; Wu H; Li Y; Zhang R; Kleeff J; Zhang X; Cui M; Liu J; Li T; Gao J; Pan B; Wu W; Wang W; Zhou L; Guo J; Dai M; Zhang T; Liao Q; Lu Z; Zhao Y
    Cancer Immunol Immunother; 2020 Aug; 69(8):1477-1492. PubMed ID: 32285172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.